Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study Academic Article uri icon

Overview

MeSH Major

  • APOBEC-1 Deaminase
  • Carcinoma, Transitional Cell
  • Clonal Evolution
  • Drug Resistance, Neoplasm
  • Mutagenesis
  • Mutation
  • Neural Cell Adhesion Molecule L1
  • Urinary Bladder Neoplasms

abstract

  • This crossover study of patients with advanced RCC demonstrated potent tivozanib anti-tumour activity. Safety and tolerability profiles were acceptable and consistent with the established adverse event profile of tivozanib.

publication date

  • May 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2018.02.009

PubMed ID

  • 29547835

Additional Document Info

start page

  • 87

end page

  • 94

volume

  • 94